SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of Thiola EC (tiopronin), a new enteric-coated formulation of Thiola…Original Article
FDA Approves Thiola EC (tiopronin) for the Treatment of Cystinuria
